1-2 of 2
Marc Sanson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

Available to Purchase
Aram Ko, Mohammad Hasanain, Young Taek Oh, Fulvio D'Angelo, Danika Sommer, Brulinda Frangaj, Suzanne Tran, Franck Bielle, Bianca Pollo, Rosina Paterra, Karima Mokhtari, Rajesh Kumar Soni, Matthieu Peyre, Marica Eoli, Laura Papi, Michel Kalamarides, Marc Sanson, Antonio Iavarone, Anna Lasorella
Journal: Cancer Discovery
Cancer Discov (2023) 13 (3): 702–723.
https://doi.org/10.1158/2159-8290.CD-22-0376
Published: 01 March 2023
View article titled, LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
Open the PDF for LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL in another window
Includes: Supplementary data
Journal Articles

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Open Access
Funda Meric-Bernstam, Rastislav Bahleda, Cinta Hierro, Marc Sanson, John Bridgewater, Hendrik-Tobias Arkenau, Ben Tran, Robin Kate Kelley, Joon Oh Park, Milind Javle, Yaohua He, Karim A. Benhadji, Lipika Goyal
Journal: Cancer Discovery
Cancer Discov (2022) 12 (2): 402–415.
https://doi.org/10.1158/2159-8290.CD-21-0697
Published: 01 February 2022
View article titled, Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
Open the PDF for Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study in another window
Includes: Supplementary data